ArticleRespiratory medicine case reports2017
Pembrolizumab reactivates pulmonary granulomatosis.
Article in Respiratory medicine case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2019Pooled it
- Evaluating Sarcoid-Like Reactions in Melanoma Patients Treated With Pembrolizumab: A Systematic Review.Cureus · 2026Review
- Article
- Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review).International journal of oncology · 2022Review
- Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review.Frontiers in oncology · 2022Article
- Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II.Southern medical journal · 2021Article
- Adalimumab-induced sarcoidosis-like reaction involving oral cavity in rheumatoid arthritis: a case-based review.Clinical rheumatology · 2021Review
- The dark side of immunotherapy.Annals of translational medicine · 2021Review
- Sarcoid-like reaction in cases treated by checkpoint inhibitors.Medical oncology (Northwood, London, England) · 2021Review
- Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab.Respirology case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or their therapies. Immunotherapy has gained a lot of interest in the past few years and has recently gained approval as first line therapy in multiple advanced stage malignancies. Pneumonitis has been described as complication of such therapy. Granulomatous inflammation has been only rarely reported subsequent to immunotherapy. We describe a case of granulomatous inflammation reactivation affecting the lungs in a patient previously exposed to Pembrolizumab and have evidence of a distant granulomatous infection. We discuss potential mechanisms of the inflammation and assert the importance of immunosuppression in controlling the dis-inhibited immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.